Why Did My Insurance Deny Wegovy? 15 Reasons + Your 2026 Fix-It Plan
Published:
·12 min readSo your insurance denied Wegovy. That is the worst part — already over with. The good news: your denial almost certainly falls into one of 15 buckets, and many of them are fixable once you know which bucket you are in. The denial letter in your hand tells you which. From there, the next move is matching the exact phrase on your letter to the right action — a corrected prior authorization, a formal appeal, a formulary exception, a peer-to-peer review, or a cash-pay path.
▶ Run the Denial Decoder
Pull out your denial letter, find the phrase that starts “Your request was denied because…” and match it below.
First — what kind of “denial” actually happened to you?
People say “my insurance denied Wegovy,” but four very different things can happen, and each one has a different fix. The fastest way to lose time is to fight the wrong problem.
| What just happened | What it actually is | Your first move |
|---|---|---|
| Pharmacy texted you that your Wegovy is not covered | Pharmacy rejection — often a missing prior authorization, not a true denial | Call your insurer and ask: “Was a prior auth submitted? Was it approved or denied?” |
| Your doctor's office called and said the PA was denied | Prior authorization denial — the formal “no” from your insurer | Get the denial letter and note the exact reason |
| You got a letter or EOB saying coverage was denied | Claim or coverage denial | Read the letter carefully — the reason is usually in one paragraph |
| You were on Wegovy and suddenly got denied at refill | Renewal denial — continuation criteria were not met or paperwork lapsed | Ask whether the issue was a missing weight check-in, expired PA, or formulary change |
Why did my insurance deny Wegovy?
Your insurance denied Wegovy for one of 15 reasons. The five denial buckets to check first:
Plan excludes weight-loss medications
The plan covers other drugs but never Wegovy
Prior authorization incomplete or missing documents
Usually a fixable paperwork problem, not a true 'no'
BMI or comorbidity rules not met
Or the documentation did not prove you qualify
Step therapy required
Your plan requires you to try a cheaper drug first
'Not medically necessary'
Usually code for 'we did not see the proof we needed'
The other denial paths — formulary exclusion, lifestyle attempt missing, invalid diagnosis code, renewal denied, concurrent GLP-1 use, oral Wegovy coverage lag, Medicare weight-loss-only denial, and indication mismatch — each has its own playbook. We cover all 15 below.
Jump to the Denial Decoder →The Wegovy Denial Decoder: match your letter to your fix
Pull out your denial letter or open your insurer's member portal. Find the line that starts with “Your request was denied because…” or “This claim was not approved due to…” Match it to a row below.
Sources: NovoMedLink Wegovy Prior Authorization access guidance; Aetna and Cigna current published policy examples; HealthCare.gov internal appeals guidance; CMS Medicare GLP-1 Bridge program announcement. Verified May 18, 2026.
| The phrase on your letter | What it actually means | Fixable? | What to do next | What your doctor needs to attach | Who has to act |
|---|---|---|---|---|---|
| "Prior authorization required" / "PA needed" | A PA may never have been submitted, or the pharmacy ran your script before one was approved | Yes — usually fast | Have prescriber submit PA right now | Plan PA form, current BMI, diagnosis codes, comorbidities, lifestyle documentation | Prescriber's office |
| "Missing information" | The plan did not get the documents it needed | Yes | Resubmit a corrected PA before appealing if your plan allows it | BMI/weight history, comorbidity codes, chart notes, prior weight-loss programs | Prescriber |
| "Does not meet clinical criteria" / "Criteria not met" | Plan says the proof was not there | Often yes | Pull your plan's exact Wegovy criteria; appeal each unmet item line by line | Targeted evidence for every criterion | Prescriber |
| "Not medically necessary" | Often a vague label for 'we did not see proof of our criteria' | Often yes | Letter of medical necessity + peer-to-peer review | Detailed clinical letter from prescriber matched to plan criteria | Prescriber |
| "BMI does not meet plan threshold" | Current or starting BMI was missing, too low, or misread | Sometimes | Confirm whether plan uses starting or current BMI; correct as needed | Starting BMI, current BMI, dates, height/weight chart | Prescriber |
| "No documented comorbidity" | Plan did not see qualifying diagnoses on file | Sometimes | Add the diagnosis codes for any real, documented conditions | Hypertension, type 2 diabetes, dyslipidemia, OSA, CVD records if they exist | Prescriber |
| "No proof of lifestyle / weight-loss attempts" | Plan requires documented diet, exercise, or program history | Often | Submit dated proof or complete the requirement | PCP notes, dietitian visits, structured program records | You + prescriber |
| "Not on formulary" / "Non-formulary" | Wegovy is not on your plan's covered-drug list | Sometimes | Request a formulary exception + letter of medical necessity | Reason Wegovy is needed and why formulary alternatives will not work | Prescriber |
| "Plan does not cover weight-loss medications" / "Benefit exclusion" | Plan flat-out excludes obesity drugs | Usually hard — but not zero | Check for the CV or MASH indication if real; HR/employer request; Medicare GLP-1 Bridge or cash-pay path | Documentation of an alternate covered indication if applicable | You + employer + prescriber |
| "Must try preferred alternative first" / "Step therapy" | You have to try a cheaper drug before Wegovy | Often | Step-therapy exception or document a prior trial | Prior trial, contraindication, intolerance, or clinical rationale | Prescriber |
| "Invalid diagnosis code" | Wrong ICD-10 code on the submission | Usually | Correct the code — but only if the diagnosis is real and documented | Chart note matching the diagnosis | Prescriber |
| "Renewal denied" / "Patient not benefiting" | Continuation criteria were not proven (weight loss, dose stability) | Often | Submit baseline weight, current weight, percent loss | Starting weight, current weight, % loss, dose history, dates | Prescriber |
| "Concurrent GLP-1 therapy" | Plan flagged overlapping use with another semaglutide or GLP-1 product | Usually fixable | Clarify medication list and stop date for the other GLP-1 | Med list, discontinuation note | Prescriber |
| "Oral Wegovy not covered" | The pill launched January 2026 and many formularies have not caught up | Sometimes | Ask whether the pen is covered, or file a formulary exception for the tablet | Formulary screenshot, prescriber rationale | Prescriber |
| "Medicare denied — weight loss only" | Standard Part D does not cover GLP-1s for obesity alone | Often, with the right path | Check eligibility for the Medicare GLP-1 Bridge (launching July 1, 2026) | Historical BMI at GLP-1 start, Part D enrollment | Prescriber |
Picking the wrong fix wastes weeks.
Paperwork problems need a corrected submission, not a formal appeal. True plan exclusions need a different path entirely — appeals rarely fix them. Match your row first.
If your row says “missing information,” “criteria not met,” or “not medically necessary,” do not start with cash-pay yet. Build the corrected PA or appeal packet first — these are the most fixable buckets.
A safety check before any provider or cash-pay path
Wegovy is a prescription medication, not a checkout product. Before pursuing any path on this page, you and your prescriber should review the FDA prescribing information together. The key things to know:
- ⚠Do not use Wegovy if you or any family member has a history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), or if you have had a serious allergic reaction to semaglutide or any Wegovy ingredient.
- ⚠Wegovy should not be used with other semaglutide-containing products (Ozempic, Rybelsus, compounded semaglutide) or any other GLP-1 receptor agonist.
- ⚠Talk to your prescriber about pancreatitis, gallbladder disease, kidney function, severe GI symptoms, diabetic retinopathy, low blood sugar risk if you take insulin, pregnancy plans, upcoming surgery, and any other medications you take.
This information is not a substitute for medical advice. Always discuss treatment with a licensed prescriber before starting, switching, or stopping a GLP-1.
What should I do in the first 24 hours after Wegovy is denied?
The next 24 hours matter more than the next 24 days. Most people spend day one being upset (fair) and emailing their doctor “what now?” (not enough). Here is what actually moves the needle.
Get the denial in writing
If all you have is a pharmacy text or a phone call, ask your insurer to email or mail the formal denial letter. Without it, you cannot appeal.
Find the exact denial reason
It is in one paragraph, usually starting with "Your request was denied because…"
Note your appeal deadline
Most commercial plans give you 180 days for an internal appeal. Medicare Part D drug appeals must be requested within 65 days of the denial notice. The deadline is on the letter.
Call your insurer and ask three questions
"Was this a pharmacy rejection, a prior authorization denial, or a claim denial?" • "What exact criterion was not met?" • "What documentation would satisfy that criterion?"
Call your doctor's office
Ask: "What was actually submitted in the PA?" Sometimes a critical field — like baseline BMI or a comorbidity diagnosis code — was left blank.
Save everything
Screenshot your plan's formulary page. Save the denial letter as a PDF. Log every phone call with the rep's name, date, and time.
Do not assume full retail is your only path
Wegovy's listed original price is $1,349.02, but current cash-pay, savings-offer, and Medicare Bridge paths may be much lower depending on eligibility.
What are the most common Wegovy denial reasons?
Here is the deeper version of the 15-reason decoder for the five buckets most people land in, plus the two that confuse people most.
Your plan excludes weight-loss medications
This is the hardest one. Some employer health plans — especially self-funded ERISA plans run by large employers — flat-out exclude all anti-obesity medications. This is not a documentation problem you can fix with a better letter. The plan never covered Wegovy and never will, no matter how perfect your prior auth is.
NovoMedLink, Wegovy's own provider-facing access site, says obesity benefit exclusions will most likely receive automatic denials — and that a generic letter of medical necessity will not reverse it.
What to do if this is your bucket:
- →Check for a covered indication. Wegovy injection is FDA-approved for chronic weight management, reducing major cardiovascular event risk in adults with established cardiovascular disease (prior heart attack, stroke, or peripheral artery disease) and either obesity or overweight, and treating adults with noncirrhotic MASH with moderate-to-advanced liver fibrosis (F2–F3). Wegovy tablets are FDA-approved for chronic weight management and cardiovascular event risk reduction, but NOT for MASH. Talk to your doctor before assuming a denial can be re-filed under a different indication.
- →Ask your HR or benefits team. Some employers will add GLP-1 coverage if enough employees ask. It is a long shot, but it costs nothing.
- →Medicare GLP-1 Bridge if you are on Medicare Part D (covered in detail below).
- →Cash-pay paths. They exist. They are a lot cheaper than they used to be. The cash-pay floor in 2026 is far lower than what people remember from 2023.
Prior authorization incomplete or missing — the most common and fixable bucket
Your insurer did not deny Wegovy because you do not qualify — they denied it because they did not get the right documents.
Most common gaps:
- ·No recent in-clinic BMI measurement. Self-reported height and weight do not count.
- ·Missing comorbidity diagnosis codes. If you have hypertension or sleep apnea but the codes were not on the PA, the plan cannot see them.
- ·No lifestyle modification documentation. Most plans want 3–6 months of dated proof. Aetna's published example asks for 6 months of a comprehensive weight-management program; Cigna's published example asks for at least 3 months of behavioral and dietary modification.
BMI or comorbidity threshold not met
Wegovy's FDA-approved indication for chronic weight management is adults with a BMI ≥30, or BMI ≥27 with at least one weight-related medical condition. Most insurers follow that bar, but some plan documents use stricter criteria than the FDA label. Verify your specific plan's Wegovy policy instead of relying on a generic insurer name.
→ Confirm your plan's threshold in writing. Call the number on the back of your card and ask for the Wegovy coverage criteria document.
→ Check whether your plan uses starting BMI or current BMI. This trips up people who already started losing weight before submitting the PA.
→ Look for missed comorbidities. Untreated sleep apnea, prediabetes (HbA1c 5.7–6.4%), or dyslipidemia may be in your records but not on the PA. Adding even one qualifying condition can flip a denial.
Step therapy — “try a cheaper drug first”
Your plan wants you to fail one or more cheaper weight-loss drugs before approving Wegovy. The usual suspects: orlistat, Saxenda, Qsymia, Contrave, phentermine, and sometimes Rybelsus or another GLP-1 like Ozempic. This feels insulting — and clinically, often it is. But it is appealable.
→ Document a prior trial. If you tried any of those drugs at any point, get the records. Even if it was years ago. Even if you stopped because of side effects.
→ Document a contraindication, intolerance, or prior failure. If the required drug is not appropriate for a real medical reason, your prescriber can document why it is contraindicated, likely to cause harm, previously failed, or not clinically appropriate.
→ Ask about state step-therapy protections. Some states have step-therapy exception laws, but they vary by plan type and may not apply to self-funded employer plans.
“Not medically necessary”
This is the most frustrating denial because it sounds like the insurer is questioning your doctor's judgment. Usually that is not what it means. “Not medically necessary” is almost always code for “we did not see proof of our specific criteria on the documents that were submitted.”
1. Ask your insurer for the exact criteria they applied. They have to give them to you in writing.
2. Have your prescriber write a Letter of Medical Necessity (LOMN) that addresses each criterion point by point. Generic LOMNs do not work. The LOMN must say: “Criterion 1 is met because [evidence]. Criterion 2 is met because [evidence]…”
3. If the LOMN is denied too, request a peer-to-peer review — a phone call between your prescriber and the insurer's medical reviewer. Peer-to-peer reviews often resolve denials that paper appeals did not.
Wegovy is not on your formulary
Different from a plan exclusion. “Not on formulary” means the plan covers some weight-loss drugs but Wegovy is not on their list. This is very common with the new Wegovy pill — many formularies have not added it since the January 2026 launch.
Renewal denied — “you did not lose 5%”
You were approved. You took Wegovy for months. You went to refill and got hit with a denial. Many renewal policies require documented response to treatment. Aetna's example requires at least 3 months at a stable maintenance dose plus at least 5% baseline body-weight loss. Cigna's current example also uses a ≥5% baseline body-weight-loss requirement for continuation.
Common renewal denial reasons:
· Prescriber did not put the starting weight on the renewal form
· The plan asked for “current weight” and somebody submitted weight from the wrong date
· You lost weight and your current BMI is now below the original threshold (Wegovy worked — and now the plan says you do not qualify)
What to do: Make sure starting weight, current weight, percent loss, and dose history are all on the renewal submission. If your BMI is now below 27 because Wegovy worked, your prescriber can submit a maintenance-of-weight-loss argument.
DECISION POINT: Want help instead of doing this yourself?
If you are thinking “I do not have time to do all of this,” you have a real option: Ro Body includes an insurance concierge that handles most of the PA and coverage process for you.
What Ro's concierge actually does (verified on ro.co, May 2026):
· Checks your insurance coverage free with the GLP-1 Insurance Coverage Checker
· Helps gather information needed for prior authorization
· Submits prior authorization paperwork and goes back and forth with your insurer during the PA process
· If a request is denied, keeps exploring coverage options including whether another clinically appropriate GLP-1 may be covered
· If insurance will not cover, lets you choose from cash-pay medication options if clinically appropriate, or cancel the Ro Body membership
Typical timeline
Ro says its insurance coverage process usually takes about 2–3 weeks, but can take longer if the initial request is denied.
Pricing (verified May 2026)
$39 first month, then as low as $74/month with annual plan paid upfront ($149/month on monthly billing). Medication cost is separate.
Sponsored link. The RX Index may earn a commission from Ro. Government-plan beneficiaries should read the Medicare and Medicaid sections below first — Ro says it cannot help coordinate GLP-1 coverage for government insurance plans.
What should I do during the first 7 days after a Wegovy denial?
If “appeal it” feels like a wall, this turns it into seven small moves.
Open your denial letter. Find the exact denial phrase. Run the Decoder above.
Call your insurer. Get the exact criteria they applied in writing. Confirm your appeal deadline. Note pharmacy callbacks.
Email your doctor's office with: (a) the denial reason, (b) the criteria the plan applied, (c) what your Decoder result says is needed.
Ask your doctor's office about a peer-to-peer review if your denial was "not medically necessary." Some plans process these within a few business days.
Enroll in the Wegovy savings offer (text SAVE to 83757 or visit wegovy.com — verify the current enrollment instructions). With commercial insurance and a covered prescription, the offer can bring your copay to as little as $25/month.
Decide on a backup path so you are not without medication while the appeal runs. Three options compared in detail below: NovoCare direct cash-pay, Ro telehealth cash-pay with PA support, or Sesame branded cash-pay.
Submit the corrected PA or the formal appeal. Corrected PA for paperwork issues (faster); formal appeal for clinical-judgment disputes.
Mark your follow-up date. Calendar a reminder to check status.
If a single day of this list feels overwhelming, that is a signal you may want a concierge service to take it off your plate. That is a legitimate use of money. Your time also has value.
What Wegovy prior authorization criteria do major plans publish in 2026?
| Insurer or PBM | BMI threshold | Step therapy? | Lifestyle program? | Renewal rule | Notes |
|---|---|---|---|---|---|
| Aetna (published example) | ≥30, or ≥27 with comorbidity | Varies | 6 months of a comprehensive weight-management program | ≥3 months at stable dose + ≥5% baseline body-weight loss or maintenance | Comorbidity list includes hypertension, T2D, dyslipidemia |
| Cigna (published example) | ≥30, or ≥27 with comorbidity | Varies; verify with your plan | 3 months of behavioral modification and dietary restriction | ≥5% baseline body-weight loss for 1-year continuation | Verify exact plan |
| CVS Caremark (template formularies) | Verify your specific plan | Some templates list Wegovy as preferred | Verify with your plan | Verify with your plan | Individual plan design controls |
| Medicare Part D (standard) | n/a for weight loss alone | n/a | n/a | n/a | Does not cover Wegovy for weight loss alone; may cover for MACE risk reduction if criteria met |
| Medicare GLP-1 Bridge (CMS) | ≥35 alone; or ≥30 with HFpEF, uncontrolled HTN, or CKD 3a+; or ≥27 with prediabetes, prior MI, prior stroke, or symptomatic PAD | n/a | Ongoing lifestyle modification required per CMS | Evaluated at GLP-1 therapy initiation, not current date | Launches July 1, 2026 — $50 flat monthly copay |
| Medicaid (varies by state) | State-specific | State-specific | State-specific | State-specific | Check your state's preferred drug list and MCO directly |
| UHC, BCBS, Anthem, Kaiser, Humana, Express Scripts, OptumRx | Verify your specific plan | Verify | Verify | Verify | These payers publish multiple policy variants. Pull your plan's specific Wegovy criteria from the member portal or call the number on your card |
Sources: Aetna pharmacy clinical policy bulletin (Wegovy PA non-Medicare); Cigna weight-loss GLP-1 prior authorization coverage policy PDF; NovoMedLink Wegovy access guidance; CMS Medicare GLP-1 Bridge program announcement. Verified May 18, 2026.
Does Medicare cover Wegovy? (And what the new GLP-1 Bridge changes)
What the Medicare GLP-1 Bridge is
The Bridge is a CMS pilot program running from July 1, 2026 through December 31, 2027. For eligible Medicare Part D beneficiaries, the Bridge covers three FDA-approved GLP-1 drugs when used to reduce excess body weight:
- ✅All formulations of Wegovy (injection and tablet)
- ✅All formulations of Foundayo (orforglipron, FDA-approved April 2026)
- ✅The KwikPen formulation of Zepbound only (single-dose vials and pens are NOT included)
You pay a flat $50 copay per 30-day supply — that price stays $50 regardless of dose or what phase of the Part D benefit you are in.
Who is eligible (CMS criteria)
You must be enrolled in an eligible Medicare Part D plan, AND meet one of these criteria at GLP-1 therapy initiation (not necessarily today):
Important Bridge caveats:
· No part of the $245 Bridge net price counts toward your Part D gross covered drug costs, and the $50 copay does NOT count toward your TrOOP.
· Low-income cost-sharing subsidies (Medicare Extra Help) do NOT apply to the Bridge copay — you still pay the $50.
· Coupons and discount cards cannot be applied to Bridge claims.
· Humana is the central processor for all Bridge claims, regardless of which Part D plan you are on.
· CMS evaluates BMI at the time your GLP-1 therapy started, not today — so if Wegovy is working and your BMI has dropped, your prescriber attests to your starting BMI.
What about right now, before July 1?
For Medicare beneficiaries reading this in May or June 2026, the Bridge is not live yet. Your options today:
- · Pursue the CV risk reduction indication if you have established cardiovascular disease and meet the FDA's criteria for Wegovy's MACE-reduction indication.
- · Pursue the MASH indication with Wegovy injection if you have a confirmed MASH diagnosis with F2 or F3 fibrosis.
- · Self-pay via NovoCare Pharmacy or another cash path (see the next section). Some Medicare beneficiaries who do not qualify for the Bridge will still find cash-pay cheaper than expected.
Does Medicaid cover Wegovy?
Short answer: It depends on your state. Medicaid coverage of GLP-1s for weight loss varies enormously. Several state Medicaid programs have tightened GLP-1 coverage in recent years due to budget pressure. Others added coverage. Because every state's formulary is different, there is no national yes-or-no.
What to do if your state Medicaid denied Wegovy:
- Look up your state's Medicaid preferred drug list (PDL) and check whether Wegovy is on it.
- If you are in a Medicaid managed care plan (MCO), call the MCO and ask for the Wegovy criteria.
- Ask whether your state covers Wegovy for the CV indication or MASH even if not for weight loss alone.
- Manufacturer savings offers usually exclude Medicaid beneficiaries — do not assume the Wegovy savings card applies.
How to appeal a Wegovy denial step-by-step
If your bucket is appealable — not a plan exclusion, not a Medicare-only-covers-CV situation, not a state Medicaid issue — here is how the appeal actually works.
Step 1: Know your appeal type and deadline
For most commercial plans you have 180 days from the date of the denial notice to file an internal appeal. Medicare Part D drug appeals must be requested within 65 days from the date on the initial denial notice. Marketplace plans vary. The deadline is on the letter.
Step 2: Build the appeal packet
A strong Wegovy appeal includes:
- ·The denial letter
- ·The plan's published Wegovy coverage criteria
- ·A Letter of Medical Necessity addressing each criterion point by point
- ·Current in-clinic BMI (not self-reported)
- ·ICD-10 codes: E66.01 (obesity) plus qualifying comorbidities (E11.9 T2D, I10 hypertension, E78.5 dyslipidemia, G47.33 OSA, etc.)
- ·Documentation of 3–6 months of lifestyle modification (PCP notes, dietitian visits, structured program records)
- ·Prior medication trial history with dates and reasons stopped (essential for step-therapy denials)
- ·If you have established CV disease, the appeal can cite Wegovy's FDA cardiovascular indication directly
- ·If you have MASH with F2–F3 fibrosis (confirmed by FibroScan, MR elastography, or biopsy), the appeal can cite Wegovy injection's FDA MASH indication
Step 3: File the internal appeal
Your doctor's office usually submits. You can also submit yourself through your insurer's portal. Commercial internal appeals are generally due back within 30 days for care or medication not yet received and 60 days for care or medication already received.
Step 4: Request a peer-to-peer review at the same time
A peer-to-peer is a phone call between your prescriber and the insurer's medical director. For “not medically necessary” denials, this is often more effective than paperwork.
Step 5: If the internal appeal is denied, request external review
Under the Affordable Care Act, you have the right to an external review by an independent third party. The plan's final denial letter must tell you how to request one. External reviews are binding — if the external reviewer says the plan must cover Wegovy, they have to.
Step 6: Expedited appeals
If a delay would seriously harm your health, you can request an expedited appeal — many plans must decide within 72 hours. This applies more often to CV-risk-reduction Wegovy cases than to weight-management ones, but ask your doctor.
What if my Wegovy appeal fails?
If your appeal fails, the next move depends on why it failed. A true plan exclusion usually pushes you toward an employer benefits request, a covered alternate indication if it really applies, Medicare Bridge eligibility, or an FDA-approved cash-pay path. Here are the three real cash-pay paths that work in 2026.
The manufacturer path — often the cheapest
Novo Nordisk runs NovoCare Pharmacy and the Wegovy savings offer. With commercial insurance and a covered Wegovy prescription, the savings offer can bring your copay to as little as $25/month. Without commercial coverage, the offer supports cash-pay pricing through NovoCare Pharmacy.
| Wegovy version / dose | Self-pay price | Notes |
|---|---|---|
| Wegovy pill 1.5 mg | $149/month | Starting dose |
| Wegovy pill 4 mg | $149/month until Aug 31, 2026, then $199/month | Offer terms can change |
| Wegovy pill 9 mg | $299/month | Medication cost only |
| Wegovy pill 25 mg | $299/month | Maintenance-dose tablet |
| Wegovy pen 0.25 mg or 0.5 mg | $199/month for first two monthly fills (intro through June 30, 2026) | New patients only |
| Wegovy pen 0.25–2.4 mg after intro | $349/month | Standard ongoing pen pricing |
| Wegovy HD 7.2 mg | $399/month | Higher-dose pen product |
Verify current pricing on wegovy.com or novocare.com before enrolling. Savings offers generally exclude people enrolled in government-funded prescription benefit programs such as Medicare, Medicaid, VA, DOD, or TRICARE. CMS also says coupons and discount programs may not be applied to Medicare GLP-1 Bridge claims.
This is not an affiliate path. We are telling you about it because it is often the cheapest one and you deserve to know.
The telehealth concierge path — best if you want the appeal handled
If you want someone else to handle the PA, file the appeal, switch your prescription to a covered alternative if appropriate, and have a cash-pay backup ready in case nothing works — Ro Body is the strongest fit for FDA-approved Wegovy intent in 2026.
Sponsored link. Government-plan beneficiaries: Ro says it cannot help coordinate GLP-1 coverage for Medicare, Medicaid, and similar plans.
The branded cash-pay path — best for self-pay shoppers who want provider choice
Sesame Care lists GLP-1 medication options including Wegovy pill, Wegovy pen, Zepbound KwikPen, Foundayo, and Ozempic, with Wegovy pill starting at $149/month and Wegovy pen starting at $199/month for the first two months for new Wegovy patients.
If your insurance will not budge and you would rather not pay a monthly membership fee on top of medication, this is often the lower-overhead route.
See Sesame branded GLP-1 pricing →Sponsored link. Confirm current pricing and availability on Sesame before enrolling.
What about LillyDirect?
LillyDirect is a direct-to-consumer manufacturer program that sells Zepbound directly from Eli Lilly. It does not handle Wegovy specifically (that is a Novo Nordisk product), but it is a solid path if your prescriber suggests Zepbound as an alternative after a Wegovy denial. LillyDirect exclusions apply to government plan beneficiaries.
What we actually verified for this guide
| What we verified | Source | Date |
|---|---|---|
| The 15 Wegovy denial categories | NovoMedLink Wegovy prior authorization access guidance | May 18, 2026 |
| FDA indications for Wegovy injection vs Wegovy tablets (including MASH accelerated approval applies to injection only) | Wegovy prescribing information | May 18, 2026 |
| Aetna and Cigna PA criteria examples | Aetna pharmacy clinical policy bulletin; Cigna weight-loss GLP-1 prior authorization coverage policy | May 18, 2026 |
| Federal internal appeal deadlines (180 days commercial) and 30/60-day completion windows | HealthCare.gov internal appeals page | May 18, 2026 |
| Medicare Part D Level 1 redetermination 65-day deadline | HealthCare.gov / CMS appeal guidance | May 18, 2026 |
| Medicare GLP-1 Bridge launch date, eligibility criteria, eligible drugs, $50 copay, TrOOP treatment | CMS Medicare GLP-1 Bridge program page; KFF analysis; Humana payer guidance | May 18, 2026 |
| NovoCare Pharmacy current cash-pay pricing tiers | wegovy.com cost and coverage page | May 18, 2026 |
| Ro Body membership pricing, concierge scope, 2–3 week typical timeline, government-plan limitation | ro.co/weight-loss/pricing/ and ro.co/weight-loss/insurance/ | May 18, 2026 |
| Sesame Care branded GLP-1 formulary and Wegovy pricing | sesamecare.com online weight loss program page | May 18, 2026 |
We did not use third-party appeal-success-rate statistics as a page claim because we did not independently verify them.
We are not clinicians. This page is informational and is not a substitute for medical advice. Always talk to your prescriber before changing or starting medication.
Real patient experiences
These are Ro-published testimonials, not independent interviews conducted by The RX Index. We are sharing them because the navigation experience they describe is exactly the situation many readers of this page are in. Individual results vary.
“Within two days, Ro ran my prior authorization and guided me to a savings card. When I went to CVS to pick up my prescription, it was just $25.”
Patient testimonial published by Ro at ro.co/weight-loss/coverage-checker-report. Shared via Ro. The RX Index may earn a commission from Ro.
“During the Wegovy shortages, we waited — and waited — for it to come back in stock. While I was waiting, I saw that Ro had started offering Zepbound and contacted my Ro team. They immediately switched my prescription… and got the prior authorizations completed through my insurance.”
Patient testimonial published by Ro at ro.co/weight-loss/coverage-checker-report. Shared via Ro. The RX Index may earn a commission from Ro.
Frequently asked questions
Why did my insurance deny Wegovy?
Your insurer denied Wegovy for one of 15 denial paths. The five to check first: your plan excludes weight-loss medications entirely, the prior authorization was incomplete or missing documents, you did not meet the plan's BMI or comorbidity rules (or the documentation did not prove you did), the plan requires step therapy (trying cheaper drugs first), or the request was filed as 'not medically necessary' because the proof of the plan's criteria was not there.
Is prior authorization the same as a denial?
No. Prior authorization is a step — your insurer's request for paperwork before they'll cover a drug. A denial happens when that paperwork is reviewed and rejected, or when a PA isn't submitted at all. A pharmacy text saying 'not covered' often means a PA is required, not that you were officially denied.
Can I appeal a Wegovy denial?
Yes — for most denial types. The exceptions are true plan exclusions (where the plan never covers weight-loss meds at all) and some Medicare situations where the only path is the new GLP-1 Bridge program. Even for plan exclusions, you can sometimes pursue the cardiovascular or MASH indication if it applies to you.
How long do I have to appeal a Wegovy denial?
For most commercial plans, 180 days from the date on the denial notice for an internal appeal. Medicare Part D drug appeals must be requested within 65 days from the date on the initial denial notice. Marketplace plans vary. The exact deadline is on your denial letter — do not guess.
Is appealing a Wegovy denial worth it?
For documentation-based denials (PA incomplete, missing comorbidity codes, missing lifestyle proof), almost always yes — these are the most fixable. For plan exclusions, appeals rarely work; pursue the manufacturer path, employer benefits request, or Medicare Bridge instead. For 'not medically necessary' denials, a peer-to-peer review is often the highest-leverage move before a formal appeal.
What does 'benefit exclusion' mean?
It means your plan's benefit design specifically excludes coverage for weight-loss medications — they're not on any formulary tier, period. A letter of medical necessity will not fix it. Your paths are: alternate FDA-approved indication (CV risk reduction or MASH if applicable), HR/employer request for added coverage, Medicare GLP-1 Bridge if you're on Part D, or cash-pay.
What does 'not on formulary' mean?
Different from benefit exclusion. 'Not on formulary' means the plan covers some drugs in this category but Wegovy is not on their list. The fix is a formulary exception request — your prescriber asks the plan to cover Wegovy despite it not being on the list, with documentation explaining why formulary alternatives are not appropriate.
What documents prove weight-loss attempts?
Dated records from your primary care doctor, dietitian, or structured weight-management program. PCP visit notes mentioning diet and exercise discussions count. Records from Noom, Weight Watchers, or similar programs may count for some plans. Self-reports usually do not. Aetna's example policy asks for 6 months of a comprehensive program; Cigna's example asks for 3 months of behavioral and dietary modification. Plans vary.
What BMI do I need for insurance to cover Wegovy?
Most plans follow the FDA: BMI of 30 or higher, or BMI of 27 or higher with at least one weight-related condition (type 2 diabetes, high blood pressure, high cholesterol, sleep apnea, or cardiovascular disease). Some plans set stricter thresholds. The Medicare GLP-1 Bridge uses BMI 35 or higher alone, 30 or higher with specific cardiac or kidney conditions, or 27 or higher with prediabetes or prior cardiovascular events — evaluated at GLP-1 initiation, not your current BMI.
Why was my Wegovy renewal denied after I lost weight?
The most common reasons: the prescriber's office forgot to include your starting weight, the wrong current weight was submitted, or your current BMI is now below the plan's threshold because Wegovy worked. The fix usually involves submitting baseline weight, current weight, percent body-weight loss, and dose history together, plus possibly a maintenance-of-loss argument.
Can I switch to Zepbound or Ozempic if Wegovy is denied?
Sometimes. Plans differ on which GLP-1 they prefer. Some plans cover Zepbound but not Wegovy, or vice versa. Your prescriber can submit a new PA for a covered alternative if clinically appropriate. Ozempic is FDA-approved for type 2 diabetes — using it for weight loss alone is off-label and usually denied by insurers for that purpose.
Does Medicare cover Wegovy?
Standard Medicare Part D does not cover Wegovy for weight loss alone. It may cover Wegovy for cardiovascular risk reduction if you have established cardiovascular disease and meet criteria. Starting July 1, 2026, the new Medicare GLP-1 Bridge program will cover Wegovy specifically for weight reduction at a flat $50 per month copay for eligible Part D beneficiaries.
Does Medicaid cover Wegovy?
It varies by state. Some states cover Wegovy through Medicaid; some cover it only for specific indications; some do not cover it at all. Check your state's Medicaid preferred drug list and, if you're in an MCO, call the MCO directly.
Does Ro help with Wegovy insurance appeals?
Yes — for commercial insurance. Ro Body membership includes an insurance concierge that submits prior authorizations, works with your insurer, and explores alternative covered medications if the first request is denied. Ro says its insurance process usually takes 2 to 3 weeks. Ro says it cannot help coordinate GLP-1 coverage for government insurance plans like Medicare and Medicaid. Membership is $39 the first month and as low as $74 per month with annual prepay; medication cost is separate.
Can I use a coupon if insurance denies Wegovy?
The Wegovy savings offer may bring your copay to as little as $25 per month — with commercial insurance and a covered prescription. If your plan denied Wegovy entirely, the savings offer can still support lower cash-pay pricing through NovoCare Pharmacy. Coupons and discount cards do not apply to Medicare or Medicaid claims, and CMS says they may not be applied to Medicare GLP-1 Bridge claims either.
Is compounded semaglutide the same as Wegovy?
Compounded semaglutide is not FDA-approved Wegovy and should not be described as interchangeable with Wegovy. They are made under different regulatory frameworks. If your prescriber prescribed Wegovy specifically, do not substitute compounded — talk to your prescriber about FDA-approved alternatives if the appeal fails.
What do I say when I call my insurer about a Wegovy denial?
Three questions: (1) 'Was this a pharmacy rejection, a prior authorization denial, or a claim denial?' (2) 'What specific criterion was not met?' (3) 'What documentation would satisfy that criterion?' Get the answers in writing if you can — by email or through your member portal.
Who submits the Wegovy appeal — me or my doctor?
Either, in most cases. Your prescriber's office usually has the clinical evidence and can submit faster. You can also submit yourself through your insurer's member portal. For peer-to-peer reviews, your prescriber must be on the call.
What if my appeal is denied twice?
Request an external review by an independent third party. Under the Affordable Care Act, this is your right. The plan's final denial letter must explain how to request one. External review decisions are binding — if the reviewer rules in your favor, the plan has to cover Wegovy.
Still not sure which Wegovy path is right for you?
Take our free 60-second matching quiz. We will route you to the best path based on your denial reason, plan type, and goals. No email required, no signup.
Quiz: no signup, no email required. Ro: sponsored affiliate link. Government-plan beneficiaries should read the Medicare and Medicaid sections above first — Ro says it cannot help coordinate GLP-1 coverage for government insurance plans.
This page is for informational purposes and is not medical advice. Always talk to your healthcare provider about treatment decisions. The RX Index is a pricing intelligence and comparison resource for GLP-1 telehealth providers. We may earn a commission from some provider links. That never changes which option we recommend first — the free path always comes first.
Last verified: May 18, 2026. We re-verify this page quarterly and after any major insurer, FDA, or CMS change. · Written and verified by The RX Index Editorial Team ·
Published:
Affiliate disclosure: The RX Index earns a commission when you sign up with some of the providers mentioned on this page. It does not affect what you pay, and it never determines our rankings or which providers we cover. Read the full disclosure.